{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Roller A"],"funding":["F. Hoffmann-La Roche Ltd"],"pagination":["e008185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11043740"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(4)"],"pubmed_abstract":["<h4>Background</h4>The immune status of a patient's tumor microenvironment (TME) may guide therapeutic interventions with cancer immunotherapy and help identify potential resistance mechanisms. Currently, patients' immune status is mostly classified based on CD8+tumor-infiltrating lymphocytes. An unmet need exists for comparable and reliable precision immunophenotyping tools that would facilitate clinical treatment-relevant decision-making and the understanding of how to overcome resistance mechanisms.<h4>Methods</h4>We systematically analyzed the CD8 immunophenotype of 2023 patients from 14 phase I-III clinical trials using immunohistochemistry (IHC) and additionally profiled gene expression by RNA-sequencing (RNA-seq). CD8 immunophenotypes were classified by pathologists into CD8-desert,"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials."],"pmcid":["PMC11043740"],"funding_grant_id":["N/A"],"pubmed_authors":["Cannarile MA","Serrano-Serrano ML","Valdeolivas A","Korski K","Davydov II","Staedler N","Dietmann G","Ferreira CS","Roller A","Heller A","Schwalie PC","Klaman I"],"additional_accession":[]},"is_claimable":false,"name":"Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.","description":"<h4>Background</h4>The immune status of a patient's tumor microenvironment (TME) may guide therapeutic interventions with cancer immunotherapy and help identify potential resistance mechanisms. Currently, patients' immune status is mostly classified based on CD8+tumor-infiltrating lymphocytes. An unmet need exists for comparable and reliable precision immunophenotyping tools that would facilitate clinical treatment-relevant decision-making and the understanding of how to overcome resistance mechanisms.<h4>Methods</h4>We systematically analyzed the CD8 immunophenotype of 2023 patients from 14 phase I-III clinical trials using immunohistochemistry (IHC) and additionally profiled gene expression by RNA-sequencing (RNA-seq). CD8 immunophenotypes were classified by pathologists into CD8-desert,","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-07-15T14:12:10.787Z","creation":"2026-07-06T03:08:42.188Z"},"accession":"S-EPMC11043740","cross_references":{"pubmed":["38649280"],"doi":["10.1136/jitc-2023-008185"]}}